Blog Archive
-
▼
2010
(63)
-
▼
April
(18)
- BioMarin Pharmaceutical : Positive Results for Pha...
- deCODE genetics "deCODEing Smoking: New Genetic Fa...
- Biodesix : VeriStrat® Outcomes Data in Lung Cancer...
- Johnson & Johnson Pharmaceutical Research and Deve...
- GeNO LLC : Investigational New Drug Application f...
- Spectrum Pharmaceuticals : Belinostat Data Present...
- Ariad : Preclinical Data on Its Investigational AL...
- Synta Pharmaceuticals : Results at AACR Supporting...
- Graceway Pharmaceuticals : Maxair Autohaler Remain...
- Patient Enrollment Complete in Tragara Pharmaceuti...
- Invida Group : Actelion Extends Partnership with I...
- Phadia : point of care in vitro specific IgE aller...
- Elekta : Next Generation SBRT for Lung Cancer with...
- NeoPharm : Orphan Drug Application Filing for IL13...
- Merrimack Pharmaceuticals : Enrollment in a Phase ...
- Clinical Data : Results of Phase I Studies of Sted...
- Pearl Therapeutics : Positive Results from Phase 1...
- Vectura to receive $9.5m payment and up to $25m lo...
-
▼
April
(18)
Apr 30, 2010
deCODE genetics "deCODEing Smoking: New Genetic Factors Behind Nicotine Dependence and Lung Cancer"
April 25, 2010 – Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation (SNP) in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer. Today, deCODE scientists and academic colleagues from 23 institutions in a dozen countries build on this work with the discovery of common SNPs on chromosomes 8p11 and 19q13 that among smokers increase the number of cigarettes smoked per day (CPD), a measure of nicotine addiction, and increase risk of lung cancer... deCODE genetics' Press Release -